Emmanuel O. Akala, Ph.D., director of the Center for Drug Research
and Development, has been awarded a prestigious NIH/National Cancer
Institute grant of $1,132,500 for three years to support innovative
breast cancer research.
Dr. Akala also is professor of
pharmaceutics in the Department of Pharmaceutical Sciences in the
College of Pharmacy. The project title is “Novel Nanotechnology Platform
for Breast Cancer Treatment.”
The human epidermal growth factor
receptor 2 (HER2) over expression has been reported in 20%–25% of all
breast cancers and is associated with a poor prognosis. The grant will
assist Dr. Akala to develop multifunctional polymeric nanoparticles to
test the hypothesis that tri-modal combination nanoparticles will prove
more effective with less toxicity than current standard of care
therapies for HER2-positive breast cancers. This nanotechnology platform
for breast cancer treatment will, when completed, bring to bear the
combined power of a chemotherapeutic agent, molecular targeted therapy
and HSP90 inhibitor, to overcome HER2 breast cancer resistance with
minimal toxicity.
A second grant is a collaboration between Dr.
Akala and Dr. Oleg Bol'shakov of South Ural State University in Russia.
The one-year, $110,000 grant will be funded by CRDF Global, an
independent nonprofit organization that promotes international
scientific and technical collaboration between international
researchers. Dr. Bol’shakov is a former post-doctoral fellow who trained
under Dr. Akala’s supervision.
Dr. Akala received his Bachelor
of Pharmacy degree in 1980 from the University of Ife in Ile-Ife,
Nigeria and his Ph.D. degree from the University of Manchester, England.
He also served as a DAAD Research Fellow with the German Academic
Exchange Program in1993, which gave him the opportunity to conduct
research in Germany.He is a registered pharmacist in Nigeria, Utah,
Maryland and Washington, D.C. Dr. Akala has made significant
contributions to the College of Pharmacy and was honored as the 2013
Distinguished Faculty Member of the Year” by the Howard University
School of Pharmacy Alumni Association.
About Howard University:
Founded
in 1867, Howard University is a private, research university that is
comprised of 13 schools and colleges. Students pursue studies in more
than 120 areas leading to undergraduate, graduate and professional
degrees. Since 1998, the University has produced two Rhodes Scholars,
two Truman Scholars, a Marshall Scholar, 30 Fulbright Scholars and 11
Pickering Fellows. Howard also produces more on campus African-American
Ph.D. recipients than any other university in the United States.
No comments:
Post a Comment